Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy

Table 1 Pertinent Characteristics of INVEST Patients at Baseline

Variable	N = 22576
Demographic
Age, mean (SD), years	66.1 (9.8)
Women	11770 (52.1)
Race/Ethnicity
White	10925 (48.4)
Black	3029 (13.4)
Hispanic	8045 (35.6)
Other/multiracial	577 (2.6)
Verapamil SR Strategy	11267 (49.9)
Atenolol Strategy	11309 (50.1)
History of
Myocardial infarction	7218 (32.0)
Stroke/transient ischemic attack	1629 (7.2)
Congestive Heart Failure (class I-III)	1256 (5.6)
Diabetes†	6400 (28.4)
Renal impairment‡	424 (1.9)
Peripheral vascular disease	2699 (12.0)
CABG or PCI	6166 (27.3)
Smoking (ever)	10454 (46.3)
Blood Pressure Systolic Blood Pressure, mean (SD)	149.5 (19.7)
Diastolic Blood Pressure, mean (SD)	86.3 (12.0)
Heart Rate, mean (SD), beats/min	75.5 (9.5)

Abbreviations: SD, Standard deviation; CABG, Coronary artery bypass graft; PCI, percutaneous coronary interventions.
Unless indicated otherwise, values express numbers (percentage).
†History of or currently taking antidiabetic medications.
‡History of or currently have elevated serum creatinine level but less than 4 mg/dl (354 μmol/L).

ISSN: 1471-2288